FDC Ltd, founded in 1936 as one of India’s leading integrated pharmaceutical companies and a pioneer in Oral Rehydration Salts (ORS) with brands like Electral, Zifi, and Zocon, reported significantly lower profits amid revenue contraction for Q2FY26.
Financial Highlights:
- Revenues declined 7.98% year-on-year to ₹473 crore from ₹514 crore.
- Total expenses fell marginally 0.87% to ₹455 crore from ₹459 crore.
- Consolidated net profit plunged 61.11% to ₹28 crore from ₹72 crore.
- Earnings per share dropped 60.63% to ₹1.74 from ₹4.42.
Seasonal weakness, pricing pressures, and operational challenges led to margin collapse with operating margins at 7.15% (down 1,450 bps QoQ).
Outlook:
FDC Ltd focuses on branded formulations recovery, US market expansion (ophthalmic approvals), and cost discipline to stabilize earnings trajectory.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.